+91-8668442535
Home / Biotechnology / Plasma Fra

Plasma Fractionation Market By Product (Coagulation Factor Concentrates, Immunoglobulin, Albumin, Protease Inhibitors and Others), By Application (Neurology, Immunology, Hematology, Critical Care and Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Industry Outlook

The plasma fractionation market is set to reach from US$ 18,099.5 Mn in 2017 to US$ 33,386.6 Mn by 2026 at a compound annual growth rate (CAGR) of 7.1% during the forecast period from 2018 to 2026. Plasma fractionation is utilized for achieving large quantities of purified protein from human plasma. Researchers have been focusing diligently in understanding the role and significance of plasma derived proteins in treating chronic ailments and autoimmune diseases. Increasing demand for biologics and increasing healthcare expenditure for drug development activities together drive the plasma fractionation market growth. 

Plasma Fractionation Market

Get a sample copy for more information

Rising prevalence of autoimmune disorders and technical innovation in deriving highly purified proteins from human plasma drive the immunoglobulin market growth

Immunoglobulin are reigning the product segment for plasma fractionation market. Technical innovations in deriving highly purified proteins from human plasma and rising prevalence of autoimmune disorders drive the immunoglobulin market growth. They are primarily of 5 classes (D,G,M,A,E) and several subclasses, responsible for consolidating the immune system. Albumin is gaining huge attention among researchers owing to its drug binding properties and its effective use as drug formulating agent, medical device coating, surgery sealants and vaccine ingredient.

Plasma Fractionation Market

Get a sample copy for more information

Increasing morbidity and lack of effective biological treatment drive the neurology applications market growth

According to World Health Organization (WHO), approximately 450 million people are reported annually to be suffering with mental illness. Neurology is dominating the application segment for plasma fractionation market. The chief attributes governing its market growth are increasing morbidity and lack of effective biological treatment for neurological disorders. Recently newer antibodies have been developed to hinder the process of protein clusters misfolding which causes Alzheimer’s and Parkinson’s disease. Immunology application will be the fastest growing segment in the near future owing to the significant rise in immunocompromised patients and technological advancement in the development of immunoglobulin to counteract disease manifestations associated with immunosuppression.

Plasma Fractionation Market

Get a sample copy for more information

Increasing number of patients suffering with chronic disease and presence of state of the art healthcare infrastructure drive the market growth in North America

North America is the supreme leader in global plasma fractionation market representing 38% share. The dominance is attributed to major factors such as increasing number of patients suffering with chronic diseases and presence of state of the art healthcare infrastructure. As per the statistics provided by Center for Disease Control and Prevention (CDC), 1 in every 6 American is living with chronic disease. Europe holds 25% market share owing to the existence of key players such as Biotest AG, Sanquin, Octapharma AG, Grifols, S.A. and supportive regulatory environment provided by the European Medical Agency (EMA). Asia Pacific is responsible for 17% share and will showcase impressive growth during the forecast period on account of rise in per capital income and affordable reimbursement scenario for plasma fractionation products utilized during treatment of chronic ailments.

Plasma Fractionation Market

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026

Report Scope by Segments

The market segmentation comprises of by product, by application and geography.

ATTRIBUTE DETAILS
Research Period  2017-2027
Base Year 2018
Forecast Period  2019-2027
Historical Year  2017
Unit  USD Million
Segmentation

 By Product (2016–2026; US$ Mn)
 • Coagulation Factor Concentrates
 • Immunoglobulin
 • Albumin
 • Protease Inhibitors
 • Others

 By Application (2016–2026; US$ Mn)
 • Neurology
 • Immunology
 • Hematology
 • Critical Care
 • Others

 Geography Segment (2016–2026; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of Asia Pacific)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of MEA)

Biopharmaceuticals actively engaged in providing plasma fractionation products are Baxter International, Inc., Biotest AG., CSL Limited, Grifols, S.A., Green Cross Corporation, Japan Blood Products Organization, Kedrion Biopharma, Inc., Octapharma AG., Sanquin and Shire, Plc.

Key questions answered in this report

  • What are the latest inorganic and organic market growth strategies adopted in plasma fractionation market?
  • Which biopharmaceutical companies are providing plasma fractionated products for treating chronic ailment?
  • What are the latest technical innovation associated with human plasma protein purification?
  • What are the clinical use of immunoglobulin?
  • What is the prevalence rate of neurological disorders and its treatment by using antibodies?
  • What is the plasma fractionation market growth in developing nation such as Asia Pacific, Latin America and Middle East & Africa?
Choose License Type
Budget Buying
Executive Summary - Brief Global Market Size - Current & Forecast
Regional Market Size - North America
Country Market Size - US
Company Profile – 1
Trusted By
Godaddy
Published Date:  Mar 2019
Category:  Biotechnology
Report ID:   59635
Report Format:   PDF
Pages:   120
Rating:    4.2 (69)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support